Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$11.03
+0.26 (+2.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $86.4M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.7B
P/E
N/A
•EV/EBITDA
41.0x
↑ROE
-6.1%
↓Gross Margin
38.6%
↓Debt/Equity
0.51
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.0%
FCF CAGR
—
FCF margin
7.3%
FCF / Net income
-1.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.18B · net income $-63.5M · FCF $86.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.18B | $1.18B | $1.18B | $1.29B | $1.37B |
| Net Income | $-63.5M | $-63.5M | $39.9M | $66.9M | $155.5M |
| EBITDA | $96.7M | $96.7M | $194.9M | $215.0M | $260.1M |
| EPS | -0.19 | -0.19 | 0.12 | 0.20 | 0.46 |
| Gross Margin | 38.6% | 38.6% | 43.2% | 50.6% | 56.2% |
| Operating Margin | 1.9% | 1.9% | 6.2% | 11.0% | 15.9% |
| Net Margin | -5.4% | -5.4% | 3.4% | 5.2% | 11.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.51 | 0.51 | 0.43 | 0.49 | 0.39 |
| Current Ratio | 1.60 | 1.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $86.4M | $86.4M | $129.9M | $-1.9M | $-116.7M |
| Returns | |||||
| ROE | -6.1% | -6.1% | 3.5% | 5.7% | 13.0% |
| Valuation | |||||
| P/E | — | — | 82.17 | 60.75 | 27.28 |
| EV/EBITDA | 40.97 | 40.97 | 18.32 | 20.57 | 17.26 |
| P/B | 3.55 | 3.55 | 2.84 | 3.45 | 3.55 |
| Growth & Yield | |||||
| Revenue Growth | -0.5% | -0.5% | -8.5% | -5.9% | — |
| EPS Growth | -258.3% | -258.3% | -40.0% | -56.5% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.2%
Start / end P/E
n/dx → n/dx
EPS bridge
0.12 → -0.19
Residual
-14.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.